Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Bruce Leicher sold 1,861 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $16.00, for a total transaction of $29,776.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Bruce Leicher also recently made the following trade(s):
- On Tuesday, November 21st, Bruce Leicher sold 803 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $13.15, for a total transaction of $10,559.45.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded up $0.05 during trading on Monday, reaching $16.30. 571,269 shares of the company were exchanged, compared to its average volume of 921,225. Momenta Pharmaceuticals, Inc. has a 1 year low of $11.85 and a 1 year high of $19.46. The firm has a market cap of $1,250.00, a PE ratio of -20.38 and a beta of 1.80.
Several equities analysts have recently weighed in on MNTA shares. Cowen set a $15.00 target price on shares of Momenta Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, November 1st. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, December 4th. BidaskClub lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $18.00 target price on shares of Momenta Pharmaceuticals in a report on Tuesday, January 30th. Two equities research analysts have rated the stock with a sell rating and ten have given a hold rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $15.30.
ILLEGAL ACTIVITY NOTICE: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/12/momenta-pharmaceuticals-inc-mnta-svp-sells-29776-00-in-stock.html.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.